Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Capital Expenditures (2021 - 2024)

Verrica Pharmaceuticals (VRCA) has 4 years of Capital Expenditures data on record, last reported at $16000.0 in Q3 2024.

  • For Q3 2024, Capital Expenditures fell 75.38% year-over-year to $16000.0; the TTM value through Dec 2025 reached $16000.0, down 40.74%, while the annual FY2024 figure was $27000.0, 92.54% down from the prior year.
  • Capital Expenditures reached $16000.0 in Q3 2024 per VRCA's latest filing, up from $11000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $311000.0 in Q1 2021 and bottomed at $5000.0 in Q1 2022.
  • Average Capital Expenditures over 4 years is $112428.6, with a median of $65500.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: tumbled 98.39% in 2022, then soared 243.94% in 2023.
  • A 4-year view of Capital Expenditures shows it stood at $237000.0 in 2021, then crashed by 72.15% to $66000.0 in 2022, then skyrocketed by 243.94% to $227000.0 in 2023, then plummeted by 92.95% to $16000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $16000.0 in Q3 2024, $11000.0 in Q2 2024, and $227000.0 in Q4 2023.